
References

- **Arroyo PJ, Bash JA, Wallack MK. (1990):** Activespecific immunotherapy with vaccinia colon oncolysate the mmunomodulatory and antitumor effects of IL-2 and interferone alpha in a murine hepatic metastasis Cancer Immunol Immunthe; 31: 305
- **Asher AL ,M1ule JJ ,Kasid A , et al (1991):**Murine tumor cells transduced with the gene for TNF J. Immunol .146, 3227 –3234 .
- **Bates SE. (1991)** Clinical applications of serum tumor markers. Ann. Intern. Med.;115: 623- 638.
- **Beauchemin N ,Benchimo S, Cournoyer D. et al. (1987)**Isoiation and characterization of full –length functional cDNA clones For human carcinoembryonic antigen.Mol. Cell Biol. ;7:3221-3230.
- **Bennett SR, Carbone FR, Karamalis F,Flavell Miller JF, Heath WR (1998)** Induction help for cytotoxic-T-cell responses is mediat by CD 40 signalling Nature 393 : 478- 480
- **Berd D, Maguire HC, McCue P. (1990):** Treatment of metastatic melamoma with autologus TCV. J Clin Oncol; 8:1858
- **Biro, S.; FU, Y.; YU, Z. and EPstein, S.(1993):** I nhibitor effects of antisense oligodeoxynucleotides targeting c-mye mRNA on smooth muscale proliferation and migration.proc Natl. Acad. Sci. USA 90 : 654

□ **Brand, D.L; Lan, M.S.; Metzgar, R.S. and Finn, O.J. (1989):** :Specific, major histocompatibility complex unrestricted recognition of tumor associated mucins by human cytotoxic T- cells *proc. Natl . Acad Sci. USA* 86-7159

□ **Brichard, V.; VAN pel , A . and Wolfel, T.(1993)** : The tyrosinase gene codes for an antigen recognized by autologous cytolytic T- lymphocytes on HLA –A2 melanomas. *J. Exp .Med.* 178-489.

□ **Brown JP, Klitzman JM, Hellstrom I, et al. (1988):**Antibody response of mice to chemically induced tumors .*Proc .Natl. Acad. Sci.*;75:955-958.

□ **Burnet, F.M. (1970):** The concept of immunological surveillance. *Prog Exp Tumor Res*, 131-27.

□ **Bystnyn JC, Henn M, Li J, Shroba. (1992):** Entification oimmunogenic human melanoma in a polyvalent nome vaccine *Ancer*; 52:5948

□ **Cabone G, Borrello MG, Molla A,et al. (1991):**Activation of ras –oncogenes and expression of tumor –specific Transplantation antigens in methylcholanthrene –induced murine Fibrosarcomas. *Int. J. Cancer*;47: 619-625

□ **Casali A, Giontra T, Rinald, M, et al. (1988):** Treatment of malignant pleural effusions with intracavitary *Corynebacterium parvum* *Cancer*; 62:806

□ **Cerutti L, Simanis V (2000):** Controlling the end of the cell cycle. *Curr Opin.Genet Dev* 10(1): 65-69

□ **Chen L, Ashe S, Brady WA, et al. (1992):**
Costimulation of anti tumour immunity by B7 counter -
receptor for T-lymphocyte molecules CD 28 and CTLA-4
Cell; 71:1093-1102

□ **Ciccone E, Pende D, Viale O, et al. (1992):**
involvement of HLA class I alleles in NK cell-specific
functions J. Exp. Med. ; 176:963-971

□ **Colombo MP, Ferrari G, Parenza M, et al. (1991):**Gcsf. gene transfer suppresses tumorigenicity of
murine adeno Cell, 50: 555-563

□ **Corton RS, Kumar V, Robbins SI. (2002) :**
Neoplasia Pathologic Basis of Disease 239-305

□ **Cortan, R.; Kumar, V.; Robbins, S. (1999):**
Pathologic basis of disease. Philadelphia: WB Saunders.
241-303.

□ **Coulie PG, Karanikas V, Colau D, et al. (2001):**
A monoclonal cytolytic T-lymphocyte response observed
in a melanoma patient vaccinated with a tumor-specific
antigenic peptide encoded by gene MAGE-3 Proc
Nati Acad Sci U S A 98:10290

□ **Coulie PG, Bruggen P (2003)** Tcell responses of
vaccinated cancer patients . Curr opin Immunol 15 : 131.

□ **Cunningham TJ, Olson KB, Laffn R. (1969):-**
Treatment of advanced cancer with active immunization.
Cancer, 24 : 932

□ **Davidoff AM and Iglehart JD. (1992)** Immune response to p53 is dependant upon p53/HSP 70 complexes in breast cancer Proc. Natl. Acad . Sci. USA; 89:3439-3442.

□ **DeBelles, G.; Consami, i.; Caramenti, B .et al .(1991)** :Mixed mode fluorescent DNA sequencing biotechnique .16 :1112.

□ **Deingardt FW, Falk LA. (1979)** Saimiri herpes-viruses and neoplasia Adv.Cancer Res; 19:167-205

□ **DeLellis RA, Dayal V. (1987)**The role of immunohistochemistry in the diagnosis of poorly differentiated neoplasms.Semin. Oncol; 14:173-

□ **Dudley ME, Wunderlich JR, Robbins PF,et al. (2002)** Cancer regression and autoimmunity in patients after clonal repopulation with antitumor tympocytes. Science 298:850

□ **Dvorak HF. (1986)** Tumor : Wounds that do not heal. M. Engl J. Med.; 315: 1651-1659.

□ **Dye Es, and North RJ (1981)** T-cell mediated immunosuppression as an obtacle to adoptive ImmunotherapyJ. Exp. Med. ; 154:1033

□ **Eder JP, Kantoff PW, Roper K, et al . (2000)** A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.Clin Cancer Res 6:1632

□ **Finer, M.H.; Dull, T.J; Win, L.; Farson, D.and Roberts, M.R. (1994)** :Kat a high- efficiency retroviral

transduction system for primary human T – Lymphocytes.BLOOD, 89:49.

□ **Foley E.G(1957)** Antigenic properties of methylcholanthrene- Induced tumors in mice of strain of origin cancer Res;B:835.

□ **Gannon JV, Greaves R, Liggan R, et al (1990).**Activating mutations in p53 produce a common conformational effect Embo j; 9: 1595-1602

□ **Gansbacher B, Zier R, Daniels b, ET AL (1990)** IL-2 gene transfer into tumor cells abrogates tumorigenicity And induces protective immunity J. Exp. Med. ; 172:1214

□ **Gold P and Freedman So, (1965)**Specific Carcinoembryonic antigens of the human digestive system J. National cancer inst. : 32:1229-1243.

□ **Goodman GE, Hellstrome I, Nicasie C, et al. (1990)** Phase I trial of murine monoclonal antibody L6 in breast, colon , ovarian and gastric cancersJ. Clin. Oncol.; 8:1083

□ **Grana x, Garriga j, Moyal x (1998)** Role of the retinoblastoma protein family pRB ,p107 and p130 in the negative control of cell growth. Oncogene 17: 3365 – 3383

□ **Green N.H.(1954):** An Immunological concept of cancer : A preliminary report ;Br.Med.J2:1374.

□ **Grimm EA and Rosenberg SA. (1989)**The human lymphokine-activated killer cell phenomenon
Lymphokins : 279-31

□ **Grom, H.; Marconi, L.A.; Barbus, C.F. ET AL. (1992)** : In vitro combinational immunoglobulin library .
Proc Natl .Acad. Sic, USA, 89 : 3576.

□ **Hallahan De., Spriggs DR, Beckett MA et al. (1989)**.Increased tumor necrosis factor and m RND alter cellular Exposure to ionizing radiation

□ **Hanna MG Jr. and key ME. (1982)**
Immunotherapy for metastasis enhances subsequent chemotherapy Science; 217:367.

□ **Hans Schreiber, (1999):** Tumor Immunology in “fundamental Immunology” fourth edition, Edited by Wiliam E. Paul; Chapter 37, 1238.

□ **Hellstrom, I, Hellstrom, K.F.; Siogren, H.O.et al. (1971)** :Demonstration of cell mediated immunity to human neoplasms of various histological types. Int .J. cancer, 7:1

□ **Hernandez J, Garcia-Pons F, Lone YC, Firat H,et al .(2002)** Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A 99:12275

□ **Herr HW and Laudone VP(1988)** Intravesical therapy for superficial cancer .Cancer P.L

□ **Hollstein M, Sidransky D, Vogelstein B, et al. (1991)** P53 mutations in human cancers Science ; 253 :49-53

□ **Honohan, D. and Weinberg, R.A. (2000):** The hallmarks of cancer. Cell, 100: 57-70.

□ **Hoon DS, Foshag LJ, Nizze AS, et al. (1990)** Suppressor cell activity in a randomized trial patients receiving active Specific immunotherapy with melanoma cell vaccine and low Dose cyclophosphamide . Cancer res.; 50:5358

□ **Hoon Ds, Irie RF. (1988):-** Gangliosides from melanoma immunomodulate response of T-cells to IL-2. Cell Immunol; 111:1

□ **Horig cs,Kaufman HL .** prostate- specific antigen vaccines for prostate cancer . Expert Opin Biol Ther 2002 ;2:395-408

□ **Horig H,lee DS,Conkrijt W,Divito J,Hasson H,laMare M,et al** Phase I clinical trial of a recombinant canarypox virus (ALVAC)vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-14.

□ **Humphrey PA , Gangarosa LN , Wong AG , et al . (1991)**Deletion – mutant epidermal growth factor receptor in human gliomas : effect of type II mutation on receptor function .Biochem : Biophys . Res. commun. ; 178:1413 –1420.

□ **Itoh K,Platsouces CD , and Bolch C M . (1988)** : Autologous tumor –specific cytotoxic T-lymphocytes in the infiltrate human metastatic melanomas .J Exp.Med; 168:1419-1441 .

□ **Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A (1996)** Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470

□ **Johnston D, el Rouby S, Bystryn JC. (1994):** Identification of melanoma cell surface antigens immunogenic in mice.Cancer Biother; 9:29

□ **Kaufman H, Kantor J, Schlom J.A. (1991)** recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). IntJ cancer ; 84 : 900-7.

□ **Kaufman HL , Flanagan K, Lee cs,Perretta DJ , Horig H.**Inserion of (IL 2) and (IL 12) genes into vscinaia virus results in effective anti –tumor response with out toxicity vaccine 2002 ; 20 :1862-9.

□ **Keller R , Geiges M and Keist R. (1990)**L-arginine – dependant reactive nitrogen intermediates as mediators of tumor cell killing by macrophags.Cancer Res.; 50:1421-1425

□ **Kerbel Rs . (1992)** Expression of multi – cytokine resistance and multigrowth factor independence in advanced stages metastatic cancer Amer . J. Pathol .; 141:519-524.

□ **Key ME, Hanna MG. (1981):** Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. 1. Synergism between BCG and line 10 tumor cells in the induction of an inflammatory response. J Natl Cancer Inst; 67: 853

□ **Khong HT, Restifo NP (2002)** Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol 3:999

□ **Klein E. (1985)**Immunological surveillance against neoplasia Harvy Lect.; 69:71-102

□ **Koyamams, OzakiA,Iwasaki Y,et al. (1986).** Randomized controlled study of postoperative adjuvant Immunotherapy with N- CWS for gastric carcinoma. Cancer Immunol .and Immunotherapy ; 22: 148 .

□ **Kripke ML (1981).** Immunologic mechanisms in UV irradiation carcinogenesis Adv. Cancer Res .; 34:69-106.

□ **Lawtance, S.K.; Smith, C.; Srivastava, R.et al (1997) :** Megabase- scale mapping of the HLA gene complex by pused filed gel electtophoresis.Science, 235:1387.

□ **Leibson PY, Loken MR, Panems LK, et al. (1979).**Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression .Proc .Natl. Acad. Sci USA; 76:2931-2941.

□ **Lemond EP,Duberuil R, Guindin A, et al. (1972).**Stimulating influence of BCG on immunity to polyoma tumors and spontaneous leukemia. J. Natl . Cancer Inst. ;47: 1013.

❑ **Lewinski, U.H, and Mavligit, G.M.(1980).** Cellular immune modulation after a single high dose of levamisole in patients with carcinoma. *Cancer*; 46:2185.

❑ **Lichtenstein A, Bick A, Cantrell J, et al. (1984).** Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with *C.parvum*. *J. Biol.*;3:371.

❑ **Likhite VV and Halpern BN.(1974).** Lasting rejection mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed *C.parvum*. *Cancer Res.*;34:341.

❑ **Lill PH and Forthner W.(1978).** Identification & cytotoxic activity of inflammatory cells recovered from progressing or regressing syngeneic UV-induced murine tumors. *J. Immunol.*; 121:1854-1860.

❑ **List AF and Greco FA (1999).** Lymphoproliferative disease in immunocompromised hosts; the role of Epstein-Barr virus. *J. Clin Oncol.*;5:1673-1689.

❑ **Livingston PO, Albino AP, Chung TJ. (1985):-** Serological response of melanoma patients to vaccines prepared from VSV stes of autologous and allogeneic cultured melanoma cells .

❑ **Lynch RG ,Graff RJ, Sirisinha S, et al.(1982).** Myeloma proteins as tumor specific transplantation antigens. *Proc. Natl. Acad. Sci. USA*;69:1540-1544.

❑ **Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, et al .(2000)** A study in advanced cancer patients of a diversified prime- and boost vaccination protocol using recombinant vaccinia virus and recombinant

nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses . J Clin Oncol 2000 ; 18:3964 – 73.

□ **Mathe G, Amiel JL, Schneider M, et al.(1969).** Active immunotherapy for acute lymphoblastic leukemia. Lancet, 1:697.

□ **Mclaughlin, S.K.; Collis, P.; Hermononot, P . et al. (1988)** :Adeno- associated virus genral transduction vector analysis of proviral structures.J.Viral. 63 : 1963.Perelson, A.S.(1989) : Immune network therapy immunol. Rev .110:5.

□ **Meigar S,Lecterc S,Least M(1999)** properties and potential- appllications of chimical inhbitors of cyclin – dependent Kinases. Pharmacol Ther 82(2-3): 279-284

□ **Miller, A.D.;Traubner, D.R.and Bultimore,C.(1992)** :Factors involveld in the production of helper – free reroviral vectors . Somat cell Genet 12:175.

□ **Mitchell MS, Harel W, Shau H. (1988)** : Active specificimmunotherapy for melanoma. Cancer Res; 48:5883

□ **Montovani A. (1990).** Tumor-associated macrophags.Curr. Opin..Immunol;2:689-692.

□ **Morse MA, coleman RE , Akabani G, Niehaus N, coleman D , Lyerly HK(1999)** Migration of human dendritic cells after injection in patients with metastatic malignancies . Cancer Res 59:65-58

□ **Mortarini R,Anichini A, Di Nicola M, Siena S, et al . (1997)** Autologous dendritic cells derived from CD34 + progenitors and from monocyts are not functionally

equivalent antigen presenting cells in the induction of melan- A/Mar 1(27-35)-specific (CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57: 5534-5541.

□ **Morton D.L, Eilber FR, Malmgren RA ,et al. (1970).** Immunological factors which influence response to Immunotherapy in malignant melanoma. Surgery; 68: 158.

□ **Morton DL, Hoon DSB, Gupta RG. (1989):-** Treatment of malignant melanoma by active specific immunotherapy. New Horizons in Tumor Immunotherapy; 665

□ **Morton DL, Hunt KK, Bauer RL. (1991);**Immunotherapy by active specific immunization of the host using mono-ecific agent. Biologic Therapy of Cancer; 627

□ **Moses HL and Yong EY.(1990).**TGF-beta stimulation and inhibition of cell proliferation Cell ; 63:245-247.

□ **Munn DH and Cheung NK. (1990).** Phagocytosis of tumor cells by human monocytes cultured in Recombinant macrophage clony –stimulating factor. J.EXP Med.; 172: 231-237

□ **Nathan CF and Murray HW.(1980)**Current concepts , the macrophags as effector cellsN, Eng. J. Med.; 303 : 622-626.J . Exp . Med .; 303;

□ **Noda K , Teshima K , Tekeuti K et al ., (1989)**Immunotherapy using the sterptococal preparation

OK- 432-for the treatment of uterine and cervical cancer.Gynecol. Oncol .; 35:367.

❑ **North RJ and Havell EA. (1988)** The antitumor function of TNF.J. Exp. Med.; 167: 1086-1099.

❑ **Nurse P (1997)** Checkpoint pathways come of age.Cell 91(7) : 865 – 867 Chi R Gould KL (1999) Regulating the onset of mitosis. Curr_Cell Biol 11:267-273

❑ **Old L J and Clark D A (1995)** : Effect of B C G infection on transplanted tumors in mouse .Nature 148:291-292

❑ **Onuma M , Yomamoto M , Yastomi Y et al . (1989)**Regression of bovine lymphosarcoma by treatment withCell – wall skeleton of Nocardia rubra. Vaccine ; 7 : 121.

❑ **Peace DJ , Chen W , Nelson H et al. (1991)**T- cell recognition of transforming proteins encoded by mutated ras protooncogenes. J Immunol .; 146:2059-2065.

❑ **Perelson, A.S.(1989)** : Immune network therapy immunol. Rev .110:5.

❑ **Piver MS , Borlow JJ, Tsuada y , et al . (1979)**.Postirradiation squamous cell carcinoma in situ of the vagina,Treatment by topical 20%5 – flurouracil creamAm. J. Obst .Gynecol .; 135:377.

❑ **Pullano TG and Sinn E (1989)**Characterization of monoclonal antibody R 256 ., specific for activated ras p21 with arginine at 12 , and analysis of breast carcinoma

of V- Harvey ras transgenic mouse .Oncogene ; 4 : 1003-1008.

□ **Rao JB, Chamberlain RS, Bronte V. (1996):** IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression . J Immunol; 156:3357

□ **Restifo NP, Spiess PJ , Karp ST , et al . (1992)** A non- immunogenic sarcoma transduced with CDNA for interferon γ elicits CD8+ T cells against the wild – type tumor .J Exp – Med.; 175:1432-1431.

□ **Restifo NP. (1996):** Recombinant anti-cancer vaccines Cancer J SciAm; 2:16

□ **Reynolds C W and Ortlando G R.(1987):**N K . cell Activity; definition of function rather than a cell type . Immunol today ; 8:172-174.

□ **Robbins, p.f.; EL-Gamil, M. and Li, Y.E.(1995) :** Cloning of a new gene encoding an antigen recognized by melanoma specific HLA-A21 restricted tumor infiltrating lymphocytes. J. immunol . 154:5911.

□ **Rosenberg SA(1991)** Adoptive cellular therapy : clinical applications.Biologic therapy of Cancer ; 214-236.

□ **Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu Pet al.(1998)**Immunologic and ‘therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Mod 4:321

□ **Rosenberg SA, (1998)** Immunologic and therapeutic evaluation of a synthetic peptide vaccine for

the treatment of patients with metastatic melanoma. Nat Med 4:321-327.

□ **Rosenberg SA. (1991)**Immunotherapy and gene therapy of cancer.

□ **Rouse BT and Worner NL . (1972)**Anti- serum induced suppression of the cellular transfer of tumor Specific immunity to syngeneic plasma cell tumor Nature New Biol .; 238: 116-117.

□ **Rouslahti E and Yamaguchi Y (1991)** Proteoglycans as modulators of growth factors activities .Cell ; 64 : 867 –869.

□ **Scheibenbogen C, Schadendorf D, Bcchrakis NE, et al. (2003)** Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as iminunological adjuvants on the T cell response to vaccination with tyrosinase peptides. Int J Cancer 104:188

□ **Schreiber H . (1989)**Idiotypic network interaction in tumor immunity Adv. Cancer Res.; 41 :291-321.

□ **Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, et al.(2002)** Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279

□ **Schultz N, Oratz R, Chen D, Zelenuiuch-Jacquotte A, Abeles G,Bystryr JC (1995):-** Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine; 13:503

❑ **Schwartz GK, Iison D, Saltz 1. et al (2001)** Phase II study of the cyclin dependent Kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma . J Clin Oncol 19 (7) : 1985 – 1992

❑ **Sedegah M, Brice GT ,Rogers WO,et al.(2002)** Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting ; characterization of effector and memory CD8 (+) – T-cell populations . Infect Immun 2002;70 : 3493-9 .

❑ **Senderowicz . AM (2001)** Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 15(1): 1- 9

❑ **Shiria M and Watanab S. (1990)** Intratumoral injection of OK 432 and lymphokine – activated killer activity in peripheral blood of patients with hepatocellular carcinoma Eur .J. Cancer ; 26 : 956.

❑ **Skillings JR , Levine M . Rayner HL , et al (1991)** Levamisole and 5 FU therapy for resected colon Cancer congra.Can Med, Assoc. J. ; 144:297.

❑ **Slingluff CL, Vollmer R. (1988):**Stage II malignant melanoma: assessment of ASI. J Surg Oncol; 39:139

❑ **Smedts F , Ramaekers F , Troyanvosky , et al .(1992)**Keratin expression in cervical cancer.Am . J. Pathol .; 141:497-511

❑ **Solomon E and Borrow J , (1991)**Chromosome aberrations and cancer .Science ; 254:1153-1160.

❑ **Soloway MS and Perry A. (1987)** BCG. For treatment of superficial transitional cell carcinoma of the Bladder in patients who have failed thiopeta and / or mitomycin .J. Urol .; 137:871.

❑ **Spellman CW and Tomasi TB .(1983)**Ultraviolet light – induced suppression of antigen presentation J.Clin . Immunol .; 80:87-102

❑ **Stein, C. And Cohen, J.(1989)** : Phosphorothioate oligodeoxynucleotides; inhibitors of gene expression. London : Macmillan, 97.

❑ **Srivastava P and Old LJ. (1988).**Individually distinct transplantation antigens of chemically induced Mouth tumors. Immunol .Today ; 9 :78-83.

❑ **Steinman RM (1991)**The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 9: 271 –296.

❑ **Suto R, Srivastava PK. (1995):** A mechanisms for the specific immunogenicity of heat shock protein chaperoned peptides.Science ; 269 : 1585.Vosika GJ , Goldman A , Parker R. (1979) Intralesional immunotherapy of malignant melanoma .Cancer ; 44 :495.

❑ **Tagguchi T . (1986)**Clinical efficacy of lentinan on patients with stomach cancer.Cancer Detect . Prev.; 1 : 333.

□ **Tainsky MA , Yin Y , Bischoff FZ , et al . (1992)** Wild – type P53 restores cell cycle control and inhibits gene Amplification in cells with mutant p53 alleles. Cell ; 70 : 937-948.

□ **Tang MN , Park BH ., Koeppen HKW , et al . (1991).** Long – term inhibition of tumor growth by T.N.F. Proc. Natl .Acad .Sci. USA , 88: 3535-3539.

□ **Tang ZY , Wu MC .(1989)** Primary Liver cancer . page , 113.

□ **Tevathia SS, Tevethia MJ , Lewis AJ ., et al . (1983)** Biology of SV40 transplantation antigen IX. Virology , 128:319-330.

□ **Thomas L ; (1969)** Discussion of cellular and humoral aspects of the hypersensitive states . Science 65-267.

□ **Thomas R, Chambers Mboytor R, MacFadyen Anderson J (1999)** Immature humane monocyte derived dendritic cells migrate rapidly to draining lymph nodes after Intradermal injection for melanoma immunotherapy Melanoma Res 9:474-495

□ **Thurner B, Van der, Driesch P, Bocker CB, Schuler G (1999a)** Monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage four melanoma J Exp Med 190:1669-1678

□ **Trinchieri . G (1989).** Biology of natural killer cells . Adv. Immunol. 47:187-376

□ **Tsang KY , Zhu M , Even J , Gulley J , Arlen P , schlom J .** The infection of human dendritic cells With recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells . Cancer Res 2001 ; 61 : 7568 – 76 .

□ **Uhr JW , Picker LJ , Tucker TF , et al (1992)**Cancer dormancy : isolation and characterization of dormant lymphoma cells.Immunology of Cancer : cellular and molecular mechanisms : 29-30.

□ **Urban JL and Schrieber H . (1983)** Selection of macrophage resistant progressor tumor variants by the normal host.J. Exp. Med. ; 157:642-656.

□ **Uriel. J. (1989)**Retro differentiation and fetal patterns of gene expression in cancer.Adv. Cancer Res. .; 29: 127-174.

□ **Van der Bruggen P, Traversri C, Chomez P, et al. (1991)** A gene encoding an antigen recognized by cxytolytic T lymphocytes. On a human melanoma. Science ; 254:1943-1647.

□ **Van der Burg SH, Menon AG, Redeker A, et al.(2002)** Induction of p53 -specific immune responses in colorectal cancer patientsreceiving a recombinant ALVAC-p53 candidate vaccine. Clin cancer Res 2002;8:1019-27.

□ **Van Pel A and Boon T. (1994).**Improved induction of melanoma –reactiveCTL with peptides from the melanoma antigen gp 100 modified at HLA binding residues.j immunol 157:2539.

□ **Vogelstein B and Kinzler KW.(1992).** P53 function and dysfunctionCell ; 70:523-526.

□ **Von Mehren M, Arlen P, Julley J,Rogatko A Cooperfprs HS, Meropol NJ, et a1.** The influence of

granulocyte macrophage colony- stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC – CEAB7.1) in patients with metastatic carcinoma.Clin cancer Res2001;7:1181-91

□ **Von Wauve J and Janssen PA (1991)**Review article on the biochemical mode of action of levamisole.J.Immunopharmacol.13:3.

□ **Wallack MK , Sivanandham M , Balch CM , , et al (1998).** Surgical adjuvant active specific immunotherapy for patients with stage III melanoma : the final analysis of data from a phase III , randomized , double- blind , multicenter vaccinia melanoma oncolysate trial . J Am Coll surg 1998 ; 187: 69- 77

□ **Watson JD , Hopkins NH., Roberts JW , et al .(1987)**The genetic basis of cancer .Molecular Biology of the Gene , 1006-1057.

□ **Weisburger JH and Williams GM.(1991)**Carcinogen test : current problems and new approaches.Science ,214:401-407.

□ **Whitworth PW , Pack CC , Esgro J , et al .(1990)**Macrophages and Cancer .Cancer Metastasis Rev.; 4:319-351.

□ **Winn HJ.(1961)** Immune mechanisms in homotransplantation ; Quantitative assay of immunologic activity of lymphoid cells stimulated by tumor homograft .J. Exp Med. ; 169:1557-1564

□ **Wright A , Lee JE , Link MP , et al .(1989)** Cytotoxic T- lymphocyte specific for self tumor immunoglobulin express T. cell receptor chain.J. Exp Med.; 169:1557-1564.

□ **Zoller M and Segal S. (1992)**IL-1 production by transformed fibroblasts.Int. J .Cancer , 50:450